IRADIMED CORP (IRMD) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. IRADIMED Corporation develops, manufactures, and distributes MRI-compatible medical devices, including non-magnetic IV infusion pump systems and patient vital signs monitoring systems. The company operates as a single reportable segment with sales primarily in the United States (82% of revenue) and internationally.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $21.98 million | $19.51 million |
| Gross Profit | $16.81 million | $14.84 million |
| Gross Margin | 76.5% | 76.1% |
| Net Income | $5.82 million | $4.69 million |
| Diluted EPS | $0.45 | $0.37 |
| Operating Cash Flow | $8.29 million | $4.29 million |
| Cash & Equivalents (End of Period) | $56.37 million | $50.33 million |
| Working Capital | $74.30 million | $71.02 million |
| Total Debt | $0 | $0 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 13% year-over-year, driven by a 19% increase in device sales (specifically IV infusion pumps and monitoring systems) and growth in extended maintenance agreement amortization.
- Profitability: Net income rose 24% to $5.82 million. The effective tax rate increased to 25.1% from 21.2% in the prior year, primarily due to state income taxes and non-deductible compensation expenses.
- Expense Management: General and administrative expenses remained flat, while sales and marketing expenses decreased slightly. Research and development expenses increased 67% to $0.96 million, largely due to payroll costs for the MRidium 3870 IV infusion pump system that were capitalized in the prior year.
- Cash Flow: Operating cash flow more than doubled to $8.29 million, supported by higher net income and improved working capital management, despite a timing-related increase in accounts receivable.
Guidance, Outlook, and Risks
- Outlook: Management expects higher revenue for fiscal year 2026 compared to 2025, driven by increased sales of medical devices, accessories, and disposables. Operating expenses are also expected to be higher due to increased sales, marketing, and regulatory costs.
- Dividends: On April 30, 2026, the Board declared a quarterly cash dividend of $0.20 per share, payable May 29, 2026.
- Regulatory & Tax: The company implemented changes related to the "One Big Beautiful Bill Act" (OBBBA) enacted in July 2025, transitioning from the FDII deduction to the FDDEI deduction. No material change to the annual effective tax rate is expected.
- Risks: Key risks include reliance on a limited number of products, potential delays in FDA clearances for new products, supply chain disruptions (including sole-source components), and geopolitical instability affecting trade policies and tariffs. The company is evaluating potential refunds for tariffs paid following a recent Supreme Court ruling.
Investor Verification Checklist
- Verify the sustainability of the 19% growth in device revenue, specifically the mix between IV infusion pumps and monitoring systems.
- Monitor the impact of the 67% increase in R&D expenses on future product launches and profitability.
- Assess the timeline and probability of recovering tariff costs following the recent Supreme Court ruling.
- Review the company's cash burn rate relative to its $56.4 million cash balance to confirm the "no additional capital required" assertion.
- Confirm the status of FDA clearances for any new product candidates mentioned in future filings.